DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves midday: Intel, Chipotle, Juniper Networks and more
▼ + stars: | 2023-10-27 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Intel — Shares of the chipmaker popped 9.3% Friday, a day after Intel reported third-quarter results that topped analysts' expectations. Juniper Networks — The network management software provider climbed 6.1% after exceeding Wall Street's expectations on earnings and revenue for the third quarter. Juniper earned 60 cents per share on an adjusted basis, while analysts surveyed by FactSet expected 55 cents per share. Chipotle Mexican Grill — Chipotle shares led the market higher Friday, gaining 4.5% after the company's third-quarter earnings topped expectations. While profits fell short of Wall Street's expectations, revenue topped estimates.

Persons: Pat Gelsinger, Dexcom, Stanley Black, Decker, Juniper, FactSet, Chipotle, Ford, —, Alex Harring, Samantha Subin, Yun Li, Hakyung Kim Organizations: Intel —, Intel, Juniper Networks, Revenue, Bank of America, LSEG, Enphase Energy, Chevron, Ford, UAW

☆ Dexcom stock climbs as worries surrounding weight-loss drugs fades
▼ + stars: | 2023-10-27 | by ( Angelica Peebles | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDexcom stock climbs as worries surrounding weight-loss drugs fadesCNBC's Angelica Peebles joins 'Closing Bell Overtime' to take a closer look at stock movers in the healthcare sector.

Persons: Angelica Peebles

☆ Stocks making the biggest moves after hours: Intel, Amazon, Chipotle, Enphase Energy and more
▼ + stars: | 2023-10-26 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Amazon issued fourth-quarter sales guidance ranging between $160 billion to $167 billion, while analysts polled by LSEG called for revenue of $166.6 billion. Intel earned 41 cents per share, adjusted, on $14.16 billion in revenue, while analysts polled by LSEG had expected 22 cents per share in earnings and revenue at $13.53 billion. Earnings per share came in at $4.45 versus the $3.24 per share expected by analysts polled by FactSet. Analysts polled by FactSet expected earnings of 34 cents per share and revenue at $939.6 million. Analysts polled by LSEG called for $22.64 in earnings per share and $4.015 billion in revenue.

Persons: LSEG, Ford, Dexcom, FactSet, —, Darla Mercado Organizations: Amazon, Intel, Ford —, Ford, LSEG, FactSet, Enphase Energy, Revenue

☆ As Ozempic and Wegovy take off, this tech startup just raised $20 million to tackle weight loss with data
▼ + stars: | 2023-10-24 | by ( Ashley Capoot | ) www.cnbc.com time to read: +6 min

Weight loss has always been big business, but it's exploded of late due to surging demand for Ozempic, Wegovy and other new diabetes and obesity drugs. "Whether you have five pounds to lose or 100, we want to make sure we're able to help everybody," Sharam Fouladgar-Mercer, Signos' co-founder and CEO, told CNBC in an interview. Fouladgar-Mercer said he created the company in 2018 partly because of his own struggle to manage weight throughout his life. Users can also integrate sleep data, heart rate data, and exercise data from their Apple Watch to personalize their profile even more. Fouladgar-Mercer said Signos can work well alongside Ozempic and Wegovy from Novo Nordisk and other GLP-1 treatments.

Persons: Signos, Mercer, it's, It's, GLP Organizations: Cheyenne Ventures, GV, Google Ventures, Dexcom Ventures, CNBC, Signos, U.S . Food, Drug Administration, Apple Watch, Abbott Laboratories, U.S, Novo Nordisk, Nordisk's Locations: Mercer, Novo, Europe, Fouladgar, America

☆ Wall Street braces for big tech earnings and key economic data in the week ahead as Treasury yields rise
▼ + stars: | 2023-10-20 | by ( Sarah Min | ) www.cnbc.com time to read: +6 min

Major earnings reports and economic data will be in focus next week as investors seek clarity on how the Federal Reserve will proceed from here. But next week will bring the lion's share of results including reports from mega-cap darlings Alphabet, Amazon , Meta Platforms and Microsoft . While the S & P 500 is higher by 10% in 2023, the equal-weighted index is down slightly. Of note, Tesla shares sank more than 9% on Thursday following a pessimistic economic outlook from CEO Elon Musk during the company's earnings call. Its the S & P 500's first weekly loss in three weeks.

Persons: bode, Elon Musk, We're, Sam Stovall, it's, Raphael Bostic, Ed Clissold, Ned Davis, Clissold, Katie Stockton, Rob Ginsberg, I'm, CFRA's Stovall, Stovall, Sherwin, Williams, Kimberly, Hess, Raymond James Financial, Keurig Dr Pepper, Northrop, Willis Towers Watson, Stanley Black, Rowe Price Organizations: Federal Reserve, Microsoft, Investors, CFRA, Dow Jones, Treasury, Fed, Atlanta Federal Reserve, Ned, Ned Davis Research, Wolfe Research, Chicago, P, PMI, P Global PMI Manufacturing, P Global PMI Services, Richmond Fed, Visa, Texas Instruments, General Electric, NextEra Energy, Raytheon Technologies, Dow, Inc, General Motors, Halliburton, Coca, Corning, Hilton Worldwide, General Dynamics, Dominion Freight, Mobile US, Boeing, Raymond, Technology, Whirlpool, International Business Machines, O'Reilly, Honeywell, Northrop Grumman, Mastercard, Amazon, Royal Caribbean Group, Tractor Supply, United Parcel Service, Hasbro, Southwest Airlines, Comcast, Hershey, Intel, L3Harris Technologies, Ford Motor, Energy, Chevron, Decker, Exxon Mobil, Colgate, Palmolive Locations: U.S, Atlanta, AbbVie

How GLP-1 drugs work Sorting through the facts reveals some likely winners and losers. LLY YTD mountain Eli Lilly shares year to date performance It is still early days for GLP-1 medications. Many have seen the rise of GLP-1 drugs as a threat to the medical device industry. Also, not all patients are able to tolerate GLP-1 drugs, which can cause side effects such as nausea. Among other medtech stocks, Plovanic sees GLP-1 drugs as an "incremental positive" for Dexcom, which makes continuous glucose monitors (CGMs), but an "incremental negative" for insulin pump makers like Insulet.

Persons: Insulet, Medtronic, Dexcom, BAX, NASH, Eli Lilly, Peter Verdult, Lilly, Eli Lilly aren't, Piper Sandler, Wegovy, Yasmeen Rahimi, Robbie Marcus, Marcus, hasn't, Baxter, David Low doesn't, William Plovanic, Craig Wong, Pan, Plovanic, Matt O'Brien, O'Brien, Rippling, Simeon Gutman, Morgan Stanley, Gutman, — CNBC's Michael Bloom Organizations: Novo Nordisk, Baxter International, Baxter, GLP, Citi, Novo, Bank of America, Viking Therapeutics, Pharmaceuticals, Pfizer, Amgen, Companies, Fisher, Reuters, Inspire, Systems, JPMorgan, RBC Capital, Walmart, underperformance Locations: GLP, U.S, DaVita, ResMed

☆ How is the rise of GLP-1 weight loss drugs affecting market action? Jim Cramer explains
▼ + stars: | 2023-10-11 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

CNBC's Jim Cramer on Wednesday explained how GLP-1 drugs are influencing market action. GLP-1 drugs were initially approved to treat diabetes, but many found off-label use to help with weight loss. Popular GLP-1 drugs include Eli Lilly 's Mounjaro and Novo Nordisk 's Wegovy, the latter of which has been approved by the Food and Drug Administration for weight loss management. Even though it seems early to asses the impact of these drugs, they are already affecting stocks, Cramer said. Intuitive Surgical also saw shares slide when executives noted slowed growth in bariatric surgeries last quarter, potentially due to increased use of GLP-1 drugs.

Persons: CNBC's Jim Cramer, there'll, Eli Lilly, Cramer, Abbott Labs —, Lilly's Mounjaro Organizations: Novo Nordisk, Food and Drug Administration, Abbott Labs

☆ Stocks making the biggest moves midday: Sunnova Energy, Cal-Maine Foods, Marathon Petroleum and more
▼ + stars: | 2023-10-04 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

Check out the companies making headlines in midday trading. Carnival — Cruise line stocks rose as a group during midday trading. Sunnova Energy , Sunrun — Sunnova Energy added 2.2%, while Sunrun declined 1.1% after Truist downgraded the solar stocks to hold from buy ratings, citing near-term concerns from elevated interest rates. Cal-Maine Foods — Shares slipped 7.3% after the egg producer provided a weak earnings report, citing a dynamic market environment. Energy stocks — Energy stocks fell as a group during midday trading Wednesday as oil prices slid more than $3 a barrel.

Persons: Truist, Insulet, Wayde McMillan, Phillips, —, Alex Harring, Samantha Subin Organizations: Fluor Corporation, UBS, Cruise, Royal Caribbean, Sunnova Energy, Energy, Cal, Maine, FactSet, Intel, — Energy, Marathon Petroleum Locations: Fluor, Insulet

☆ Analysts predicted new obesity medicines would be blockbusters. Now they’re raising their forecasts
▼ + stars: | 2023-09-16 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Fernandez sees a total addressable market of $140 billion to support patients with obesity. He expects there is a potential for GLP-1 drugs to become as common and widely used, much like statins are used to lower cholesterol. Morgan Stanley's Flynn estimates a 30% share of the diabetes market would generate $109 billion on a worldwide basis for GLP-1 drugs. Layer in a 15% to 30% share of the obesity market and that equates to worldwide sales of $97.4 billion to $194.8 billion. Guggenheim's estimates also assume that oral GLP-1 drugs that are currently in development are able to come to market a few years from now.

Persons: Seamus Fernandez, Fernandez, Lilly, Eli Lilly, Morgan Stanley, Terence Flynn, Eli Lilly's Mounjaro, Insulet, Canaccord, William Plovanic, Plovanic, It's, Morgan Stanley's Flynn, Flynn, Novo, Michael Bloom Organizations: Wall, Novo, American Heart Association, Food and Drug Administration, Novo Nordisk, Iqvia, Disease Control Locations: GLP

☆ Stocks making the biggest moves midday: General Motors, Stellantis, Planet Fitness, Adobe and more
▼ + stars: | 2023-09-15 | by ( Alex Harring | ) www.cnbc.com time to read: +4 min

Nucor — The steelmaker fell 6.1% after offering worse-than-expected guidance for third-quarter earnings, with the company pointing to pricing and volume challenges. Core & Main — The infrastructure stock retreated 4.1% a day after it announced a secondary stock offering. The bank said Apellis has a favorable risk/reward ahead of third-quarter earnings. The Wall Street firm said the resumption of loan repayments introduce bookings risk to food delivery. The Wall Street firm said its pessimistic outlook was changing despite recent underperformance in the reinsurance space.

Persons: Stellantis, Chris Rondeau, Rondeau, Craig Benson, Nucor, Raymond James, Needham, Charles Shi, Lam, Goldman Sachs, Apellis, MoffettNathanson, Estée Lauder, Goldman, Yun Li, Jesse Pound, Samantha Subin, Pia Singh, Brian Evans, Lisa Kailai Han Organizations: UAW, General Motors Wentzville, General Motors, Ford, United Auto Workers began, Workers, CNBC, LSEG, PTC Therapeutics, Medicines Agency's, Medicinal Products, Arm, Investment, Bloomberg News, Apple, Dexcom, ASML Holding, Lam Research, Taiwan Semiconductor, Adobe, Bank of America, JPMorgan, Apellis Pharmaceuticals, Waste Systems Locations: Wentzville , Missouri, New Hampshire, Wells, underperform

☆ Obesity drugs’ popularity put a dent in these stocks. Why analysts say they’re still worth buying
▼ + stars: | 2023-09-08 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +7 min

Industry analysts are insisting that new weight loss and diabetes drugs like Ozempic won't hurt the demand for insulin pumps and continuous glucose monitors, but most investors aren't buying it. The answer may depend on who you listen to and whether you see GLP-1 drugs as a help or a hinderance to the category. DXCM 3M mountain In the quarter to date, Dexcom shares are down nearly 19%. Dexcom shares are down more than 7% year to date. TNDM 3M mountain Tandem Diabetes shares have fallen significantly this year.

Persons: Ozempic, Danielle Antalffy, Eli Lilly's Mounjaro, hasn't, Dexcom, Piper Sandler, Matt O'Brien, O'Brien, Paresh Dandona, semaglutide, Travis Steed, Steed, — CNBC's Michael Bloom Organizations: UBS, Nordisk's, Novo, New, of Medicine, Tandem Diabetes, Tandem Diabetes Care, Diabetes, Jacobs School of Medicine, Biomedical Sciences, University of Buffalo, Novo Nordisk's, Bank of America Locations: CGMs

☆ Stocks making the biggest moves midday: Roku, Tesla, AMC, AeroVironment and more
▼ + stars: | 2023-09-06 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

Roku also boosted its third-quarter revenue guidance to between $835 million and $875 million, versus prior guidance of $815 million. AMC Entertainment — Shares tumbled 36.8% after AMC said it plans to sell up to 40 million new shares to raise cash. The issuance of additional shares was expected after it converted preferred APE shares into AMC common stock in August. Revenue also beat expectations, coming in at $152 million, versus the $129 million expected. Harley-Davidson — The motorcycle maker gained 3.16% after it authorized the repurchase of up to an additional 10 million shares.

Persons: Roku, Tesla, Elon Musk, Apple, AeroVironment, Thoma Bravo, Davidson, Zscaler, LSEG, Wall, Dexcom, —, Macheel, Alex Harring, Michael Bloom Organizations: Street, SpaceX, Twitter, AMC, Journal, Bank of America, LSEG, Revenue, Healthcare, Dominion Energy, Dominion, Southwest Airlines —, Southwest Airlines Locations: Virginia, China, Enbridge, Southwest

☆ Amazon Pharmacy automates discounts to help insulin patients get pledged prices
▼ + stars: | 2023-08-15 | by ( Patrick Wingrove | ) www.reuters.com time to read: +3 min

Aug 15 (Reuters) - Amazon.com (AMZN.O) said on Tuesday its online pharmacy will automatically apply manufacturer-sponsored coupons to more than 15 insulin and diabetes medicines to help patients access discounts pledged by the drug industry. Vin Gupta, Amazon Pharmacy's Chief Medical Officer, said the report highlighted the need to make it easier for patients to get their insulin at the lowest possible prices. Amazon Pharmacy will also automatically apply available discounts to diabetes-related medical devices from manufacturers Dexcom and Insulet, including continuous glucose monitors and pumps, as well as to other cardiometabolic medicines such as Novo's powerful weight-loss drug Wegovy. American Diabetes Association Chief Executive Officer Charles Henderson said Amazon's automated discounting would help the 37 million Americans with diabetes more easily access the treatments they need. So, we're going to create options that gives them access to these medications," Amazon Pharmacy Vice President John Love told Reuters.

Persons: Eli Lilly, Lilly, Elizabeth Warren, Vin Gupta, Wegovy, Charles Henderson, John Love, Patrick Wingrove, Sandra Maler Organizations: Amazon Pharmacy, Novo Nordisk, Sanofi, Amazon, Congress, American Diabetes Association, Walgreens, Reuters, Thomson Locations: New York

☆ As weight loss drug stocks rallied on a landmark study, these stocks were over sold, analysts say
▼ + stars: | 2023-08-11 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +8 min

However, the pharmaceutical companies are making the case that weight loss can improve health, and possibly lower health-care costs over time. But analysts have said the news isn't all bad for such stocks, and many were fell too low on Tuesday. Deutsche Bank analyst Imron Zafar estimated Thursday that bariatric surgery accounts for about 5% of Intuitive Surgical's U.S. robotic surgery business, but has been driving much of the company's growth. Some of the surgeons Zafar spoke with said any drop off in bariatric surgery was likely to be offset by increased use of the robot for other procedures. But they expect the drugs will remain necessary because GLP-1 drugs have yet to show they improve fibrosis, which is associated with NASH.

Persons: nonalcoholic steatohepatitis, NASH, Abbott, Robbie Marcus, Marcus, Marcus doesn't, Goldman Sachs, Goldman, Stryker, Smith, Zimmer Biomet, Bariatric, Imron Zafar, Zafar Organizations: Novo Nordisk, Abbott Laboratories, CNBC, JPMorgan, Companies, Inspire Medical Systems, Resmed, Philips, Nephew, Deutsche Bank, Madrigal Pharmaceuticals, Sagimet Biosciences, Akero Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, Madrigal Locations: U.S

☆ Stocks making the biggest moves after hours: Intel, Ford, Roku, Enphase Energy and more
▼ + stars: | 2023-07-27 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

Intel projected third-quarter adjusted earnings of 20 cents per share, compared with estimates of 16 cents per share, according to Refinitiv. Ford — The auto giant added 1% after raising full-year guidance and beating expectations for the second quarter. Ford reported 72 cents in adjusted earnings per share on $42.43 billion, while analysts surveyed by Refinitiv estimated 55 cents earned and $40.38 billion in revenue. First Solar — The solar stock gained 6.6% after solidly beating Wall Street expectations in the second quarter. T-Mobile — The telecommunications stock shed 1.6% on a mixed earnings report for the second quarter.

Persons: Ford, Refinitiv, Enphase, FactSet, Dexcom, Boston Beer Organizations: Intel, Enphase Energy, Refinitiv, Wall, Mobile, Boston Locations: California, Arbuckle , California

☆ Who Should Be Tracking Their Glucose?
▼ + stars: | 2023-07-12 | by ( Dana G. Smith | More About Dana G. Smith | ) www.nytimes.com time to read: +1 min

But in recent years, glucose has become one of the trendiest biometrics to track for people striving to optimize their health. That’s in large part because of the increasing accessibility of a tool called a continuous glucose monitor, or C.G.M. C.G.M.s monitor levels of glucose — the body’s main source of energy — in real time. A tiny needle-like sensor sticks into the skin and reads glucose levels in the fluid between cells. Now, there are at least five companies that market and sell apps and C.G.M.s to people without diabetes, claiming that knowing your glucose levels can help you lose weight and improve your health.

Persons: Abbott, Dexcom

☆ The rise of continuous glucose monitors
▼ + stars: | 2023-05-26 | by ( Erin Black | Jeniece Pettitt | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThe rise of continuous glucose monitorsAccording to the Center for Disease Control and Prevention, more than 37 million people in the U.S. have diabetes. Diabetics must monitor their blood sugar, a task traditionally done with glucometers by pricking your finger over and over again for drops of blood. But over the last decade, technology like continuous glucose monitoring has been on the rise. Abbott and Dexcom are the two most dominant players in the space. CNBC spoke with both companies about the technology inside CGM's.

☆ 10 stocks that are gaining market share for their disruptive innovations like AI, according to a portfolio manager
▼ + stars: | 2023-03-18 | by ( Laila Maidan | ) www.businessinsider.com time to read: +7 min

AI can be placed under the broad category of disruptive technology, which refers to innovations that change consumers' habits and displace old markets. Then, you have public cloud infrastructure that connects it all together, such as Amazon Web Services or the Google Compute Engine which provides infrastructure as a service (IaaS). For this reason, instead of taking the approach of creating something as narrow as an AI ETF, the ETF is focused on anything that signals disruption to an entire industry and changes the status quo. They have a "tremendous" market share in AI applications, and companies are hungry for their products, he noted. Analog Devices (ADI) provides technology that can translate atmospheric information into digital data to mean something to the hardware.

☆ Silicon Valley Bank signed exclusive banking deals with some clients, leaving them unable to diversify
▼ + stars: | 2023-03-12 | by ( Rohan Goswami | ) www.cnbc.com time to read: +4 min

All required the companies to open or maintain bank accounts with SVB and use the firm for all or most of their banking services. Silicon Valley Bank had exclusivity clauses with some of its clients, limiting their ability to tap banking services from other institutions, SEC filings show. Upstart held its IPO in 2020, two years after DocuSign's debut. As with Upstart, SVB set strict limits on the value and type of accounts that Sprout could hold elsewhere. The contract included an exception for international bank accounts but required that Limelight use only SVB's business credit cards.

☆ Dexcom shares fall on news Apple is progressing on glucose tracking for watch
▼ + stars: | 2023-02-22 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDexcom shares fall on news Apple is progressing on glucose tracking for watchCNBC's Steve Kovach joins the 'Halftime Report' to report on Dexcom shares dropping on news that Apple is making progress on including a glucose tracking feature on the Apple Watch.

☆ Dexcom drops on report that Apple has made glucose tracking breakthrough
▼ + stars: | 2023-02-22 | by ( Melissa Lee | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDexcom drops on report that Apple has made glucose tracking breakthroughA new breakthrough by Apple could be bad news for medical device company Dexcom. With CNBC's Melissa Lee and the Fast Money traders, Karen Finerman, Dan Nathan, Courtney Garcia and Guy Adami.

☆ Cramer's lightning round: Triton International is not a buy
▼ + stars: | 2023-02-10 | by ( Krystal Hur | ) www.cnbc.com time to read: 1 min

Loading chart...Triton International Ltd : "I'm going to have to say, let's take a pass on that one." Loading chart...Baxter International Inc : "I'd rather see you in Dexcom ." Loading chart...A. O. Smith Corp : "A. O. Smith is the kind of company that makes stuff, does things, returns capital to shareholders. Unity Software Inc : "Unity Software stinks." Loading chart...BigBear.ai Holdings Inc : "How do I say, sell, sell, sell, sell, sell."

☆ Stocks making the biggest premarket moves: Lyft, Expedia, Yelp and more
▼ + stars: | 2023-02-10 | by ( Michelle Fox | ) www.cnbc.com time to read: +2 min

Check out the companies making the biggest moves in premarket trading:Lyft — The ride-sharing company cratered 31.5% after issuing weak guidance in its fiscal first-quarter earnings report. Lyft said it anticipates about $975 million in revenue, lower than the $1.09 billion analysts expected, according to StreetAccount. Yelp — The consumer review platform gained more than 5% in the premarket after it posted fourth-quarter revenue of $309 million, topping analysts' expectations of $307 million. Deutsche Bank — Shares of the German bank dipped more than 3% in pre-market trading after Deutsche Bank was downgraded to underperform from neutral at Bank of America. Newell Brands — The parent company of Rubbermaid and Yankee Candle slumped 7.5% after reporting earnings that missed analysts' expectations.

☆ What diabetes is revealing about the benefits and risks of personal medicine connected to the internet
▼ + stars: | 2023-01-21 | by ( Ellen Sheng | ) www.cnbc.com time to read: +4 min

Devices such as insulin pumps, which go back decades, and continuous glucose monitors, which monitor blood sugar levels 24/7, are increasingly connected to smartphones via Bluetooth. Sleep apnea, Type 2 diabetes and remote health careIt's not just diabetes where the medical device market is offering patients new benefits from remote monitoring. The number of internet-connected medical devices grew during the pandemic, as lockdowns created a big push to treat people at home. Multiple forms of medical cybersecurity riskIndustry security experts categorize cybersecurity risks of medical devices into three buckets. Many medical devices such as insulin pumps require patients to create online accounts to download data to a computer or smartphone.

☆ These health care stocks are expected to rally at least 20% this year
▼ + stars: | 2023-01-16 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Health care stocks were able to outperform the broader market in 2022. The Health Care Select Sector SPDR ETF dipped 3.6% in 2022, far better than the broader S & P 500 , which slumped 19.4%. CVS is rated a buy by 58% of analysts with an average price target implying a 28% upside. Nearly three out of five analysts rate the stock a buy, with an average price target reflecting an upside of almost 22%. About 75% of UnitedHealth analysts rate it a buy, with an average price target implying a 20% upside.

Search resuls for: "Dexcom"

25 mentions found